AVGO
Broadcom
-- 180.660 TSLA
Tesla
-- 418.100 NVDA
NVIDIA
-- 137.340 PLTR
Palantir
-- 73.200 AMD
Advanced Micro Devices
-- 130.600 
NEWS
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily dosing, and proof of target engagement. The company has initiated dosing in Alzheimer's patients, including those with TREM2 variants. Vigil plans to report complete Phase 1 data, including results from the AD patient cohort, in Q1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment